Signals Inbox·July 19, 2026·Consumer Health

Is Neko Health really worth nearly $7B today?

Neko Health has real demand, strong repeat behavior and an unusually polished preventive-health product. But nearly $7 billion prices in a global clinic network and technology-platform economics that do not exist yet.

Q1Why did Neko Health suddenly become a nearly $7B company?

Neko Health became a nearly $7 billion company after raising $700 million for its US expansion. The Series C came only 18 months after a $260 million round had valued the company at approximately $1.8 billion.

Lightspeed Venture Partners led the new financing, with O.G. Venture Partners as co-lead. Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD also participated. Individual investors included Mark Zuckerberg and Priscilla Chan, Maria Sharapova, Thierry Henry, Ari Emanuel and Claudia Schiffer.

The reported valuation therefore increased almost fourfold between the two rounds. Neko had also expanded from a small Scandinavian operation into eight clinics across Sweden and Britain, while preparing to open in New York.

The speed is remarkable. Neko only started serving paying customers in 2023, yet it has already raised more than $1 billion.

Neko Health’s funding history

Q2Is Neko Health’s nearly $7B valuation actually confirmed?

The nearly $7 billion Neko Health valuation is credible, although the company did not publish the exact figure itself. Its announcement confirmed the $700 million financing and named the investors, while the Financial Times reported a valuation of almost $7 billion.

The small discrepancy probably comes from reporters using different sides of the transaction. A valuation of roughly $6.3 billion before the investment would become $7 billion after adding the new capital.

Whether the final number is $6.5 billion or $7 billion barely changes the analysis. Both figures sit far above what Neko’s current revenue appears to support.

Q3Did Neko Health reach $7B unusually fast?

Neko Health reached nearly $7 billion unusually quickly for a company built around physical medical clinics. It was founded in 2018, opened its first commercial location in 2023 and reached the reported valuation roughly three and a half years later.

Healthcare software companies can move faster. OpenEvidence, for example, reached a higher valuation within four years of founding. Neko faces heavier constraints because every new market requires locations, equipment, medical staff and regulatory approvals.

Investors are therefore pricing Neko as a future global health platform before it has proved the economics of a large international clinic network.

Q4How much revenue is Neko Health making now?

Neko Health probably generates around $30 million to $45 million in annualized scan revenue today. The company has not disclosed consolidated revenue, so we estimated the range from its customer volumes, prices and clinic growth.

Neko had completed 10,000 scans by January 2025 and more than 100,000 by the latest financing. It added at least 90,000 scans over approximately 18 months, equivalent to an average pace of 60,000 per year.

A scan currently costs £299 in Britain and SEK 2,750 in Sweden. At those prices, the historical pace would represent approximately $19 million to $24 million in annual revenue.

Current activity should be higher because several clinics opened during that period. Neko said its overall scan volume increased sixfold in one year, while London activity grew approximately fivefold. A present pace of 90,000 to 115,000 annual scans produces our $30 million to $45 million range.

The Swedish parent company’s accounts cannot settle the question. They showed only SEK 17.9 million in 2024 net sales, but they also contained substantial investments in and receivables from subsidiaries. Those numbers clearly exclude much of the clinic activity.

Revenue evidence behind our estimate

Q5Is Neko Health’s revenue multiple too high?

Neko Health’s revenue multiple is currently extreme. A $7 billion valuation divided by estimated annualized revenue of $30 million to $45 million produces a multiple of roughly 155 to 230 times revenue.

Fast growth deserves a premium, especially when customers return and demand exceeds available capacity. Even so, a multiple above 150 assumes much more than successful clinic expansion.

Investors are already paying for a large US network, automated medical workflows, employer and insurer partnerships, valuable longitudinal data and additional services built around the annual scan. Most of those businesses remain small or undeveloped today.

Q6Is Neko Health still growing fast enough to support $7B?

Neko Health is growing exceptionally fast, although its absolute size remains modest for a $7 billion company. Completed scans increased more than tenfold between its last two major funding announcements, while the reported valuation rose approximately 3.9 times.

That comparison favors Neko: customer activity expanded faster than its valuation.

The company also moved from a limited Swedish launch into four London clinics, Manchester and Birmingham. Demand reportedly continued to exceed supply after those openings.

The harder stage begins now. Neko must reproduce that pace across several countries without weakening customer experience, retention or clinic economics. Hypergrowth from 10,000 scans is impressive; sustaining it beyond several hundred thousand will be far more difficult.

Q7Is Neko Health’s 350,000-person waitlist real demand?

Neko Health’s 350,000 registrations show strong interest, but they are not the same as 350,000 customers. Around 100,000 people had completed a scan, meaning Neko had served roughly 29% of everyone who registered.

The backlog still looks more credible than a typical startup waitlist. Appointments repeatedly sold out, and demand remained above capacity after Neko opened additional British locations.

The company has also converted tens of thousands of registrations into paid visits. The more useful question now is how much of the remaining backlog survives longer waits, new locations and higher US pricing.

Q8Are Neko Health customers actually coming back?

Neko Health’s repeat behavior looks unusually strong for a consumer medical service. The company says 75% of first-time members book and prepay for the following year before leaving the clinic.

That is stronger evidence than a satisfaction survey because the customer has already committed money. Neko had previously reported rebooking rates close to 80%, so the pattern has remained broadly stable as the company expanded.

Its Stockholm data supports the same conclusion. Follow-up visits accounted for almost 34% of scans completed there during 2024, even though many newer customers had not yet become eligible for an annual return.

Several years of retention data are still missing. A customer who prepays once may not continue indefinitely. For now, recurring behavior is one of Neko’s clearest strengths.

Q9Can Neko Health open clinics fast enough to grow into $7B?

Neko Health can expand faster than a traditional clinic network, but physical capacity will keep limiting its growth. Every customer still needs a location, medical equipment, blood collection and an in-person consultation lasting approximately one hour.

Automation could improve throughput. Neko is updating its scanning devices, integrating wearable data and reducing the amount of manual work required during each visit.

The $700 million round also gives the company enough money to open clinics before older locations have fully matured. That speeds up expansion but delays the point when investors can clearly see the economics of a normal Neko clinic.

Revenue eventually needs to rise faster than staffing, property and equipment costs. Otherwise, Neko may build an excellent healthcare chain without producing technology-platform margins.

Q10Is Neko Health really worth nearly three Function Healths?

Neko Health’s valuation looks aggressive beside Function Health. Function raised $298 million at a $2.5 billion valuation, leaving Neko valued at approximately 2.8 times more.

Function says it serves hundreds of thousands of members and has processed more than 50 million laboratory tests. Its annual membership uses roughly 2,000 Quest Diagnostics locations, giving it much broader distribution than Neko currently has.

The company also acquired Ezra, adding MRI scans to its laboratory-testing membership. That moves Function closer to Neko’s promise of combining multiple preventive-health measurements in one service.

Neko controls more of the experience. It owns its equipment, operates the clinics and presents results directly through its own medical team and software. That control may improve quality, retention and pricing power.

That still does not explain such a large valuation gap.

Neko Health compared with Function Health

Q11Is Neko Health already stronger than Prenuvo?

Neko Health has a more affordable and repeatable product than Prenuvo, but Prenuvo reached commercial scale earlier. Both companies passed roughly 100,000 completed scans, although Prenuvo did so with more locations and much higher revenue per customer.

Prenuvo’s full-body MRI historically cost around $2,500. Neko charges closer to $300 to $400 for skin imaging, cardiovascular measurements, blood analysis and a medical consultation.

Around its Series B financing, Prenuvo reported more than 110,000 members and 17 North American clinics. Industry reporting also placed its 2024 revenue near $100 million.

Neko may eventually serve a much larger population because of its lower price and annual-use model. Today, Prenuvo offers stronger evidence that preventive scanning can already produce substantial revenue.

Q12How does Neko Health’s valuation compare with public health companies?

Neko Health trades at a much higher implied revenue multiple than every relevant public healthcare company we examined. A private company growing rapidly should command a premium, but the gap is enormous.

Hims & Hers is worth roughly the same amount as Neko while expecting close to $3 billion in annual revenue. Guardant Health is growing rapidly and trades at around 16 times revenue. Tempus AI trades below six times.

Neko’s estimated multiple of 155 to 230 times sits in a different category. Investors are pricing future dominance rather than current financial performance.

Neko Health compared with public healthcare companies

Q13Have other health startups earned a 100x revenue multiple?

A few healthcare startups have recently received multiples above 100 times revenue, but the closest examples usually have stronger software economics.

OpenEvidence raised at a $12 billion valuation after reporting more than $100 million in annualized revenue. That implies a multiple near 120 times. The company also claimed usage by more than 40% of US physicians and handled millions of clinical consultations each month.

Abridge reached a $5.3 billion valuation after expanding across more than 150 health systems. Reported annual recurring revenue of roughly $117 million would imply a multiple near 45 times.

These are expensive companies, yet both distribute software at very low marginal cost. Neko needs a clinic and clinical team for each additional market. Its higher estimated multiple is therefore hard to justify through precedent alone.

Q14Does Neko Health actually find serious health problems?

Neko Health finds enough serious conditions to provide genuine medical value. Its detailed report on 4,362 Stockholm scans found previously unknown life-threatening conditions in 54 people.

The cases included melanoma, severe cardiovascular problems, metabolic disease and blood disorders. Another 174 customers had significant conditions requiring treatment, while 52 had earlier problems considered reversible.

Overall, 280 people received what Neko classified as an important finding. That equals 6.4% of everyone scanned, or roughly one person in sixteen.

The report came from Neko and had no control group, so it cannot prove that annual scans reduce mortality. It does show that the product regularly identifies problems with real clinical consequences.

Q15Could Neko Health create too many unnecessary follow-up tests?

Neko Health refers a fairly large share of customers for additional investigation. In the same Stockholm dataset, 18.7% of customers required more testing or specialist review.

Some referrals produced important diagnoses. Others did not. At least 217 customers were cleared after further tests, while the final outcome remained unknown for a large group referred outside Neko’s system.

We therefore cannot calculate a complete false-positive rate. The available data shows both sides of broad screening: meaningful disease detection alongside additional costs, anxiety and medical work.

Neko’s next clinical reports need to track every referral through to a final diagnosis. Without that, we know how often the company starts an investigation but not precisely how often that investigation proves unnecessary.

Q16Is Neko Health ready for the US now?

Neko Health is much closer to a credible US launch after receiving FDA clearance for two core devices. The agency cleared its Derma-2 skin-imaging device and Spectrum-2 cardiovascular-imaging system within the same week.

Both devices passed through the FDA’s 510(k) pathway. The clearances allow Neko to bring important parts of its proprietary technology to New York rather than relying entirely on standard equipment.

They do not validate the complete health check or prove that annual scans improve long-term outcomes. The next test is commercial.

New York customers already have access to Function, Prenuvo, executive-health clinics and major hospital systems. Neko must show that its European demand and renewal rates transfer to a more competitive American market.

Q17What can Neko Health do that competitors cannot easily copy?

Neko Health’s advantage comes from controlling the devices, software, clinics and medical experience together. Competitors can reproduce individual blood tests or scans, but matching the complete system requires hardware development, regulatory work, clinical operations and consumer design.

Its annual model also creates standardized longitudinal data. Instead of seeing one isolated result, Neko can track how the same person’s cardiovascular, skin and metabolic measurements change over time.

The clinic experience strengthens that advantage. Customers receive results during the same visit, the information is presented clearly and the environment feels less intimidating than a hospital.

Neko’s moat remains vulnerable. Function has broader distribution, Prenuvo has a larger imaging history and established healthcare groups already control clinicians and patients. Neko needs to keep improving the integrated experience faster than competitors can assemble similar services.

Q18Is preventive health big enough to support a $7B Neko Health?

Preventive health is large enough to support a $7 billion company. At an average price of $400, one million annual customers would generate $400 million in revenue. Two and a half million would generate $1 billion.

Those customer totals are realistic relative to the affluent populations of the United States and Europe. Serving them is the harder problem.

Neko would need many more clinics and probably employer or insurer distribution. A self-pay product can build a valuable premium business, but reaching millions of annual customers will require broader access.

Q19How much revenue would Neko Health need to justify $7B?

Neko Health would need between $233 million and $700 million in annual revenue for a $7 billion valuation to fit within multiples of 10 to 30 times.

A multiple of 15 times would require approximately $467 million. Compared with our current $30 million to $45 million estimate, revenue would need to increase by roughly ten to sixteen times.

Reaching that level within five years would require annual growth of approximately 60% to 73%. At an average price of $400 per visit, Neko would need about 1.17 million scans every year.

Revenue required to support a $7B valuation

Q20What would have to go right for Neko Health to be worth $7B?

Neko Health can grow into its valuation if it maintains annual growth above 60% for several years and proves that the clinic model works across multiple US cities.

Retention must remain unusually high. The current 75% prepayment rate gives Neko a strong base, but mature customers need to keep renewing after their second and third visits.

Automation must also increase appointments faster than staffing and property costs. A larger network will create little operating leverage if every new customer requires a proportional increase in clinical resources.

The strongest bull case includes revenue beyond individual scans. Employer contracts, insurance coverage, research partnerships and software services could add higher-margin income. Clinic expansion alone may not be enough.

Q21What could cut Neko Health’s valuation in half?

Neko Health could lose half its valuation while still becoming a successful company. At $150 million in annual revenue and a generous 20-times multiple, the business would be worth $3 billion.

A slower US rollout could produce that result. So could weaker retention after the first renewal cycle, expensive staffing or limited insurer interest.

Competition may also pressure prices before Neko reaches scale. Function, Prenuvo and established healthcare groups are all moving toward broader preventive-health packages.

The valuation therefore requires exceptional execution. Ordinary success would probably disappoint investors.

Q22Is Neko Health really worth nearly $7B today?

Neko Health is not worth nearly $7 billion on its current financial performance. The valuation looks clearly stretched, even though the company has built one of the most promising consumer-health businesses in Europe.

We estimate that investors are paying roughly 155 to 230 times current annualized revenue. Function Health reaches a wider customer base at less than half the valuation. Prenuvo had stronger visible revenue around a similar customer milestone. Public healthcare companies trade at a small fraction of Neko’s multiple.

The case for Neko rests on real strengths. Demand exceeds clinic capacity, customers return at unusually high rates and its medical data shows that the scans regularly uncover serious conditions. The US launch also moves forward with FDA-cleared proprietary devices.

For nearly $7 billion to make sense, Neko probably needs $300 million to $500 million in annual revenue, successful clinics across several American cities and much better operating leverage than a traditional medical network. Employer or insurer distribution would strengthen the case further.

The 75% prepayment rate makes that outcome plausible, not proven.

Neko Health may eventually be worth nearly $7 billion. Today, investors are paying for the global platform they hope it will become rather than the business it has already built.